_fingolimod-vs-interferon-beta-1a-in-pediatric-multiple-sclerosis-preview-1.jpg "Fingolimod Vs Interferon Beta-1a in Pediatric Multiple Sclerosis from fingolimod hcl Video Screenshot Preview 1")
Gallery_fingolimod-vs-interferon-beta-1a-in-pediatric-multiple-sclerosis-preview-3.jpg "Fingolimod Vs Interferon Beta-1a in Pediatric Multiple Sclerosis from fingolimod hcl Video Screenshot Preview 3")
Gallery_fingolimod-vs-interferon-beta-1a-in-pediatric-multiple-sclerosis-preview-hqdefault.jpg "Fingolimod Vs Interferon Beta-1a in Pediatric Multiple Sclerosis from fingolimod hcl Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 minute 46 seconds
👁 View: 1.9K times
Play Audio:👁 View: 1.9K times
Description:
NEJM Group
NEJM Group
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_gilenya-fingolimod-safety-monitoring-for-multiple-sclerosis-2018.webp "Aaron Boster MD")
_ms-drug-switch-gilenya-to-mavenclad-safe.webp "Aaron Boster MD")
_fingolimod-dr-ganaraja.webp "Neurology Drugs Treatment Algorithms")
_positive-benefit-risk-profile-of-fingolimod-for-patients-with-pediatric-ms.webp "NeurologyLive")
⏲ 5 minutes 26 seconds 👁 68
_looking-at-long-term-results-of-fingolimod.webp "HCPLive")
_what-you-need-to-know-about-gilenya-fingolimod.webp "National MS Society")
_gilenya-fingolimod-safety-monitoring-for-multiple-sclerosis-2018.jpg)
_ms-drug-switch-gilenya-to-mavenclad-safe.jpg)
_fingolimod-dr-ganaraja.jpg)
_positive-benefit-risk-profile-of-fingolimod-for-patients-with-pediatric-ms.jpg)
_looking-at-long-term-results-of-fingolimod.jpg)
_what-you-need-to-know-about-gilenya-fingolimod.jpg)
![[+]](/images/menu.gif){kind=small}